Skip to search formSkip to main contentSkip to account menu

dehydroxymethylepoxyquinomicin

Known as: DHMEQ cpd 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
  • K. Umezawa
  • Biomedicine & pharmacotherapy = Biomedecine…
  • 2011
  • Corpus ID: 30094626
2008
Highly Cited
2007
Highly Cited
2007
PURPOSE To investigate the involvement of the renin-angiotensin system (RAS) and the nuclear factor (NF)-kappaB pathway with… 
Highly Cited
2007
Highly Cited
2007
Immunotherapy with rituximab (chimeric anti-CD20 monoclonal antibody, Rituxan), alone or in conjunction with chemotherapy, has… 
Highly Cited
2006
Highly Cited
2006
The BRAFV600E mutation is closely linked to tumorigenesis and malignant phenotype of papillary thyroid cancer. Signaling pathways… 
Highly Cited
2005
Highly Cited
2005
We previously designed and synthesized the new nuclear factor kappaB (NF-kappaB) inhibitor dehydroxymethylepoxyquinomicin (DHMEQ… 
Highly Cited
2005
Highly Cited
2005
Adult T-cell leukemia (ATL) is an aggressive neoplasm caused by human T-cell leukemia virus type I (HTLV-I). The nuclear… 
Highly Cited
2004
Highly Cited
2004
Purpose: The objective of the study was to determine the effects of a novel selective nuclear factor κB (NF-κB) inhibitor… 
Highly Cited
2002
Highly Cited
2002
We previously designed and synthesized an NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), that showed anti…